MedTrace Logo

Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment

NCT00614939 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 572

Last updated 2011-05-19

Study results available
· View outcomes & findings →

Summary

Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to test the efficacy of once daily saxagliptin in renally impaired patients.

Conditions

Interventions

DRUG

Saxagliptin

2.5 mg once daily oral dose

DRUG

Placebo

Placebo

Sponsors & Collaborators

Principal Investigators

  • Peter Ohman, MD, PhD · AstraZeneca

  • Deborah Price, MSc · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2009-06-30
Completion
2010-03-31

Countries

  • United States
  • Belarus
  • Bulgaria
  • Croatia
  • Czechia
  • Estonia
  • Germany
  • Hungary
  • Latvia
  • Lithuania
  • Poland
  • Romania
  • Russia
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00614939 on ClinicalTrials.gov